Announcements Trials
Browse Landscape

Phase

Phase 1 28Phase 2 25Phase 3 8Phase 1/2 5Phase 4 2Phase 2/3 1

Status

Completed 4Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Plasma cell 1Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 5

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Vemurafenib × Dermatologic × Clear all
NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
5 enrolled 10 charts
Dermatologic

Melanoma

NCT01959633 2022-02-24

VEMUPLINT

Fondazione Melanoma Onlus

Phase 1/2 Completed
11 enrolled
Dermatologic

Melanoma

NCT01638676 2021-10-29

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

University of Louisville

Phase 1/2 Recruiting
55 enrolled
Dermatologic

Melanoma

NCT01512251 2020-08-17

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

University of California, San Francisco

Phase 1/2 Completed
8 enrolled 6 charts
Dermatologic

Melanoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡